Tehranolide molecule modulates the immune response, reduce regulatory T cell and inhibits tumor growth in vivo

Molecular Immunology

Volumn 47, Issue 7-8, 2010, Pages 1579-1584

  Noori, Shokoofe ^a   Taghikhani, Mohammad ^a   Hassan, Zuhair M ^a   Allameha, Abdolamir ^a   Mostafaei, Ali ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b Kermanshah University   (Iran)

Author keywords

IFN ; IL 4; Immunomodulator; T regulatory cell; Tehranolide

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 4; TEHRANOLIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ CD25+FOXP3+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMETRY; CYTOTOXICITY TEST; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HYPERSENSITIVITY, DELAYED; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; NEOPLASMS; SESQUITERPENES; SHEEP; T-LYMPHOCYTES, REGULATORY;

ANIMALIA; ARTEMISIA; MUS;

EID: 77950629650     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.01.007     Document Type: Article

References (32)

1. Amy E., James L., Maggs B., Xiao-Ming S., Gerald M., Cohen J., Chadwick P., O'Neill M., Kevin B. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by Artemisinin compounds. J. Biol. Chem. 2007, 282:9372-9382.
2. Dannull J., Su Z., Rizzieri D. Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2004, 115:3623-3633.
3. Efferth T., Benakis A., Romero M.R. Enhancement of cytotoxicity of Artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 2005, 37:998-1009.
4. Golgher D., Jones E., Powrie F., Elliott T., Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 2002, 32:3267-3275.
5. Hassan Z.M., Yaraee R., Zare N., Ghazanfari T., Sarraf Nejad A., Nazori B. Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity. Int. Immunopharmacol. 2003, 3:1483-1489.
6. Hiura T., Kagamu H., Miura S., Ishid A., Tanaka H., Tanaka J., Gejyo F. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J. Immunol. 2005, 175:5058-5066.
7. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp 3. Science 2003, 299:1057-1061.
8. Kirchhoff S.R., Gupta S., Knowlton A.A. HSP6O, Apoptosis and Myocardial Injury Cardiology Research. 1985, VA Medical Center and Baylor College of Medicine, Houston, TX, 77030 (Supplement).
9. Klayman D.L. Qinghaosu (Artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055.
10. Lafaille J.J. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev. 2005, 9:139-151.
11. Li Y., Wu Y.L. How Chinese scientists discovered qing haos (Artemisinin) and developed its derivatives. What are the future perspectives?. Med. Trop. 1998, 58:95-125.
12. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., Drebin J.A., Strasberg S.M., Eberlein T.J., Goedegebuure P.S., Linehan D.C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002, 169:2756-2761.
13. Megumi I., Takeshi I., Misako N., Toshihide N., Kenji M. IL-4 alters expression patterns of storage components of vascular endothelial cell-specific granules through STAT6- and SOCS-1-dependent mechanisms. Mol. Immunol. 2009, 46:2080-2089.
14. Meshnick S.R., Yang Y.Z., Lima V., Kuypers F., Kamchonwongpaisan S., Yuthavong Y. Iron-dependent free radical generation from the antimalarial agent Artemisinin (qinghaosu). Antimicrob. Agents Chemother. 1993, 37:1108-1114.
15. Nakase I., Lai H., Singh N.P., Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. International Journal of Pharmaceutics 2008, 354(1-2):28-33.
16. Nemanja Z., Shahin A., Arsenijevic N., Miodrag L., Eric P.K. Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Mol. Immunol. 2009, 47:28-36.
17. O'Garra A., Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol. 2000, 10:542-550.
18. Onizuk a.S., Tawara I.J., Shimizu S., Sakaguchi T., Fujita E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999, 59:3128-3133.
19. Paul C.H., Li E., Lam W., Roos P., Małgorzata Z., Zdzienicka B., Kaina T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res. 2008, 68:28-36.
20. Posner G.H., Oh C.H., Wang D., Gerena L., Milhous W.K., Meshnick S.R. Mechanism-based design, synthesis, and in vitro antimalarial testing of new 4-methylated trioxanes structurally related to Artemisinin: the importance of a carbon-centered radical for antimalarial activity. J. Med. Chem. 1994, 37:1256-1258.
21. Renxi W., Gencheng H., Jianan W., Lun S., Guojiang C., Ruonan X.u., Liyan W., Xia L., Beifen S., Yan L.i. Diabetes is not prevented by Foxp3-transduced CD4+ T cells under the IL-12R 2 promoter control. Mol. Immunol. 2008, 45:3814-3817.
22. Robert A., Dechy-Cabaret O., Cazelles J., Meunier B. From mechanistic studies on Artemisinin derivatives to new modular antimalarial drugs. Acc. Chem. 2002, 35:167-174.
23. Roncarolo M.G., Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 2007, 7:585-598.
24. Rustaiyan A., Nahrevanian H., Kazemi M. Effects of extracts of Artemisia diffusa against plasmodium berghei as a new antimalarial agent. BIT's 5th Anniversary Congress of International Drug Discovery Science and Technology (IDDBST) May 28-June 5 2007.
25. Sakaguchi S. Naturally arising regulatory Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005, 6:345-352.
26. +regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005, 6:345-352.
27. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163:5211-5218.
28. Singh N.P., Lai H. Selective toxicity of dihydroArtemisinin and holotransferrin toward human breast cancer cells. Life Sci. 2001, 79:49-56.
29. + T cells. J. Clin. Invest. 2003, 112:1437-1443.
30. Wei-Zen W., Gerald P., Morris Y., Kong M. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol. Immunother. 2004, 53:73-78.
31. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., Kaiser L.R., June C.H. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 2002, 168:4272-4276.
32. Zhang F., Gosser D.K., Meshnick S.R. Hemin-catalyzed decomposition of Artemisinin. Biochem. Pharmacol. 1992, 43:1805-1809.